NIDDK on the Road: The American Society of Nephrology, October 27 - November 1, 2009

This page is for historical and reference purposes only.  Updates to content and links will not be maintained.  Current information about NIDDK's Kidney, Urological and Hematology programs can be found at http://www2.niddk.nih.gov/Research/ScientificAreas/Kidney/, http://www2.niddk.nih.gov/Research/ScientificAreas/Urology/ and http://www2.niddk.nih.gov/Research/ScientificAreas/Hematology/.

The American Society of Nephology will meet in San Diego, California from October 27 to November 1, 2009.

Meeting Posters (PDF, 181 KB) Printer friendly version of the contents on this page



NIDDK Funding History and Opportunities

The National Institutes of Health (NIH) comprises 27 separate Institutes and Centers and is the largest biomedical research center in the world. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) was established by Congress in 1950. Within the NIDDK, the Division of Kidney, Urology and Hematology (KUH) manages programs in kidney research.

In FY09, the NIDDK awarded >$250M for kidney research.

Exploratory Research (R21) Program

The evolution and vitality of biomedical science requires constant infusion of new ideas, techniques, and points of view. These innovations may differ substantially from current thinking or practice, and may not yet be supported by substantial evidence. The NIDDK R21 program provides a mechanism dedicated to:

  • Innovative, high pay-off, paradigm-shifting projects
  • Novel technology and tool development
  • Applications of existing methods, technologies, or conceptual approaches from outside biomedical science to a problem in the NIDDK mission
  • Pilot clinical trials or clinical studies

The following projects are NOT suitable for the R21 mechanism:

  • Projects of limited scope or cost that use widely accepted approaches and methods within established fields are NOT appropriate for an R21 application.
  • A proposal designed to generate preliminary data for a longer-term project in a well-established research area is NOT appropriate for an R21 application.
  • R21s should NOT be used by new PIs to gather preliminary data for an R01.
  • R21 proposals submitted by new PIs will NOT be given special priority for funding.

Most R21 applications can be submitted in response to:

However, this NIH-wide Parent R21 announcement does not cover pilot clinical studies or secondary analyses. These can be submitted in response to:


Upcoming NIDDK Meetings

  • Genetics of Urologic Malformations

    December 8-9, 2009, Marriott Crystal City, Arlington, VA    http://www3.niddk.nih.gov/fund/other/GVUR2009/index.htm

  • Best Practices for Sample Storage: Urine as a Paradigm

    Winter 2009/2010, Washington, DC

  • Inflammation in End-Stage Renal Disease: Approaches to Treatment Challenges   

    Winter 2009/2010, Washington, DC

  • Clinical and Public Health Applications of MYH9 variants in CKD

    Spring/Summer 2010

  • Life After K: Completing the Transition to Independence

    Spring/Summer 2010, Washington, DC

  • Stem Cells in Repair, Regeneration and Tissue Engineering

    Summer 2010, Washington, DC

  • NIDDK New PI Workshop

    November 2010, Washington, DC

Selected Funding Announcements

Basic Research

Translational Research

Clinical Research

American Recovery and Reinvestment Act (ARRA)

ARRA FY09 Snapshot

FY09 Awards
1 & 2 yr R01's  22
Challenge Grants  16
2 yr R21's  26
Comp Revisions  5
Admin Supp (R's)  124
Admin Supp (U's)  33
Admin Supp (P's)  16
Admin Supp (K's)  53
Summer Students  30

 TOTAL ARRA: $84.5 million for kidney research

The pie chart presents the data in the table above as percentages. Colors depict which mechanisms were awarded according to the review method. Thus, about 52% of the funds were awarded following peer review; 40% were awarded following administrative or staff review and the remaining 8% of the funds will be awarded in FY10. Of the peer reviewed mechanisms, 18% was used to support one or two year regular research grant awards (R01s); 16% of the funds supported Challenge grants; 13% supported two year Exploratory/Developmental Research Grant Awards; and 5% supported competitive revisions. Of the funds distributed by administrative review, 17% supported supplements to R awards, 12% supported supplements to Us (cooperative awards), 5% supported P awards (centers or program projects), 5% supported career development awards and 1% supported summer students.

Administrative Supplement Funding Considerations

Administrative supplement requests were reviewed administratively by staff with expertise relevant to the proposal. Selection factors included the following:

  • Relevance of the proposal to the parent grant and determination that the activities are within the scope of the project.
  • Progress of the parent grant.
  • Appropriate and well-described plan to accomplish the goals within the proposed timeframe.
  • Expertise of the research team.
  • Appropriateness of the request to achieve ARRA goals in promoting job creation, economic development, and accelerating the pace of scientific research.
  • Availability of funds and program balance and priorities.

Small Business

Small Business Funding Opportunities

Why Seek SBIR/STTR Funds?

  • Over $1 billion are available across NIH
  • They provide seed money for high-risk projects
  • They promote and foster partnerships with collaborators - including academia!
  • Intellectual property rights are normally retained by small business
  • Funds are NOT A LOAN - no repayment!
  • Large corporations look to small companies for initial development

Small Business Innovation Research (SBIR)
http://www.zyn.com/sbir
http://grants.nih.gov/grants/oer.htm

  • The SBIR program supports innovative research conducted by small businesses to develop products for commercialization. The PI must be employed by the small business, but a research institution may be involved.

Small Business Technology Transfer (STTR)
http://www.zyn.com/sbir
http://grants.nih.gov/grants/oer.htm

  • The STTR program supports innovative research for products that have the potential for commercialization. STTR projects must be conducted cooperatively by a small business and a research institution.

Select NIDDK-Supported Small Business Projects

  • Predicting kidney stones in relatives of stone formers
  • Measurement of GFR
  • Computerized Clinical Decision Support

See Visonex, LLC at Poster SA-PO2801

    • Commercialization of embryonic kidney stem cell lines, products and kits
    • Cell Treatment for Septic Shock
    • Test for Salt-Sensitivity in Essential Hypertension
    • Prevention / Treatment of Diabetic Nephropathy
    • Intravital kidney multiphoton microscopy assays of therapeutic agents
    • Renal perfusion quantification
    • Tolerance induction in transplant patients

    IMPORTANT NIH CHANGES!!!

    Revisions to Progress Report Form: PHS 2590
    http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-139.html

    Beginning October 1, 2009, submissions of annual progress reports require the use of revised PHS 2590 forms. The revisions reflect new policy changes and include:

    • New All Personnel Report
    • New Assurance for Institutions Receiving Awards for Training of Graduate Student for Doctoral Degrees
    • Inclusion of Changes to Innovative Potential
    • Changes to the Biographical Sketch
    • Human Embryonic Stem Cell Use

    Revised forms are available at:
    http://grants.nih.gov/grants/forms.htm  



    Training and Career Development


    Post-Doctoral Training

    http://www2.niddk.nih.gov/Funding/TrainingCareerDev/.htm#Career
    Ruth L. Kirschstein National Research Service Awards (NRSA)

    • Individual (F32)
      These awards provide support for fellows who have received their M.D., Ph.D., or other doctoral-level degree. Fellows need to identify a mentor and plan a research project before applying for 1 to 3 years of funding.
      http://grants.nih.gov/grants/guide/pa-files/PA-06-373.html
    • Institutional (T32)
      In place at many major universities, these grants provide pre- and postdoctoral support to fellows at those institutions. To be appointed to a training grant, contact the director of the training program at your institution.
      http://grants.nih.gov/grants/guide/pa-files/PA-08-226.html

    Training & Career Development Timeline

    Diagram indicating training and career development timeline:An arrow depicts a timeline for the advancement of an individual’s career from Graduate or Medical School, through a Postdoctoral position and Transition to Jr. Faculty and finally to a tenured position. During the graduate or medical school, pre-doctoral programs are available for either the M.D. or the Ph.D. Postdoctoral training is handled by the same mechanism for the M.D. or Ph.D. while during the Transition to Jr. Faculty positions. Thus, the individual F30, F31, or F32 mechanisms or the institutional T32 or T35 mechanisms are utilized during the pre-doctoral stage or the post-doctoral stage. The last two stages of the timeline relate to career development and employ numerous K mechanisms, the R01 and the transition award that incorporates a K99 and a R00. The transition award is designed to move the individual from a mentored position, supported by the K99, to a position of independence with a R00.

    Loan Repayment Program
    http://www.lrp.nih.gov

    The goal of the Loan Repayment Program is to ease the debt burden clinical scientists may have incurred while attending medical school and a residency program. The NIDDK has two loan repayment programs: one for clinicians and one for pediatricians. In addition to these NIDDK programs, the NCMHD sponsors two other loan repayment programs for clinicians: one for those involved in health disparities research and another for clinical researchers from disadvantaged backgrounds. Competitive applicants must demonstrate their commitment to a research career and have a debt-to-salary ratio of at least 20 percent. The Loan Repayment Program may repay up to $35,000 a year toward each participant’s outstanding eligible educational load debt, depending on total eligible repayable debt. For more details about eligibility and to apply online, visit http://www.lrp.nih.gov.


    Career Development Awards*

    http://www2.niddk.nih.gov/Funding/TrainingCareerDev/.htm

    • K01 (Mentored Research Scientist Development Awards)
      Support Ph.D. scientists who have at least 3 to 5 years of postdoctoral training and who need to transition to independence.
    • K08 (Mentored Clinical Scientist Development Awards)
      Aimed at physician-scientists to transition them to independence.
    • K23 (Mentored Patient-Oriented Research Career
      Development Awards)
      Aimed at clinical investigators engaged in patient-based research.
    • K24 (Investigator Awards in Patient-Oriented Research)
      Support mid-career physicians in patient-oriented research with funded clinical investigations and who are mentoring young clinicians.
    • K25 (Mentored Quantitative Research Career Development
      Awards)
      Available to individuals with quantitative (E.g., engineering, mathematics, computer science, etc.) backgrounds who wish to pursue biomedical research.


    Training-Related Program Announcements

    Small Grant Program for NIDDK K01/K08/K23 Recipients (R03)
    http://grants.nih.gov/grants/guide/pa-files/PAR-09-230.html
    In the final two years of the career development grant, K recipients may apply for small grant funding for additional development support for their research.

    NIDDK Education Program Grants (R25)
    http://grants.nih.gov/grants/guide/pa-files/PAR-06-554.html
    The R25 program provides support for educational opportunities (E.g., workshops, classes) to engage students from undergraduate to graduate in research areas relevant to NIDDK.

    K99/R00 NIH Pathways to Independence

    http://grants1.nih.gov/grants/guide/pa-files/PA-06-133.html
    The NIH has another opportunity for career development. This is an ideal award for talented postdoctoral candidates on the fast-track to a productive research career. Eligible applicants must have five-years or fewer of postdoctoral research experience and may not already have an independent faculty position. The first two years of the award, the K99 phase, are intended to be the mentored career-development phase. At the end of the second year, the applicant must have secured an independent tenure-track position to continue the final three years of the award as an R01. While this award does not require U.S. citizenship or permanent resident status, the applicant must be able to remain in the United States to conduct the full five years of the proposed work.

    *All NIH fellowships and career development award mechanisms, except the K99/R00, require U.S. citizenship or permanent resident status.


    Contacts

    Kidney, Urology & Hematology (KUH) Staff

    http://www2.niddk.nih.gov/AboutNIDDK/Organization/kuh_table.htm
    Telephone: (301) 594-7717


    Director, KUH
    Robert A. Star, M.D.
    starr@extra.niddk.nih.gov

    Deputy Director, Clinical; Ped Neph Program & Renal Centers
    Marva Moxey-Mims, M.D.
    moxey-mimsm@extra.niddk.nih.gov

    Deputy Director, Basic; Renal Physiol & Diabetic Neph Programs
    Christian J. Ketchum, Ph.D.
    ketchumc@extra.niddk.nih.gov

    Chronic Renal Disease, ESRD and Minority Health Programs
    Lawrence Y. Agodoa, M.D.
    agodoal@extra.niddk.nih.gov

    Epidemiology Program and U.S. Renal Data System
    Paul W. Eggers, Ph.D.
    eggersp@extra.niddk.nih.gov

    Acute Injury and HIV Nephropathy Program
    Paul L. Kimmel, M.D.
    kimmelp@extra.niddk.nih.gov


    National Kidney Disease Education Program (NKDEP)
    Andrew S. Narva, M.D.
    narvaa@extra.niddk.nih.gov

    Genetics and PKD Programs
    Rebekah Rasooly, Ph.D.
    rasoolyr@extra.niddk.nih.gov


    Clinical Trials Programs
    John W. Kusek, Ph.D.
    kusekj@extra.niddk.nih.gov

    Development Program
    Deborah Hoshizaki, Ph.D.
    hoshizakid@niddk.nih.gov

    Hematology, Training & Career Development Programs
    Terry Rogers Bishop, Ph.D.
    bishopt@extra.niddk.nih.gov

    Hematology Program
    Daniel G. Wright, M.D.
    wrightdan@extra.niddk.nih.gov

    Urology and Kidney Cell Biology Programs
    Christopher V. Mullins, Ph.D.
    mullinsc@extra.niddk.nih.gov

    Women’s Urologic Programs
    Debuene Chang, M.D.
    changtd@mail.nih.gov


    Kidney and Urology Training
    Tracy L. Rankin, Ph.D.
    rankint@mail.nih.gov


    Kidney Pathophysiology Program
    Krystyna Rys-Sikora, Ph.D.
    ryssikok@csr.nih.gov


    NIH Center for Scientific Review (CSR)

    http://www.csr.nih.gov

    The Digestive, Kidney and Urological Sciences (DKUS) IRG contains the 3 primary study sections for kidney researchers:

    • Cellular and Molecular Biology of the Kidney [CMBK]
      Reviews basic and applied aspects of normal and abnormal renal physiology, epithelial biology, cell biology, transport biology (including osmoregulation and osmosensing), hormone action and signal transduction, vascular biology, genetic disorders, cell-matrix interactions, biophysics, and bioenergetics.
    • Pathobiology of Kidney Disease [PBKD]
      Reviews basic and clinical studies of kidney disease including pathophysiology, diagnosis, consequences and treatment of acute and chronic disorders of the kidney, and consequences of kidney disease and failure, as well as studies of the normal structure and function of the glomerulus.
    • Urologic and Kidney Development and Genitourinary Diseases [UKGD]
      Reviews normal and abnormal development of kidney, urinary tract, and male genital system, and physiologic and pathophysiologic processes of cells and tissues of the bladder, prostate, ureter, urethra, male reproductive organs, penis, and male and female pelvic floor.

    DKUS IRG Staff

    DKUS IRG Chief 
    Mushtaq Khan, D.V.M., Ph.D.
    khanm@csr.nih.gov

    CMBK SRO
    Bonnie Burgess-Beusse, Ph.D.
    bb194m@nih.gov

    PBKD SRO
    Mushtaq Khan, D.V.M., Ph.D.
    khanm@csr.nih.gov

    UKGD SRO 
    Ryan Morris, Ph.D.
    morrisr@csr.nih.gov


    IMPORTANT NIH CHANGES!!!

    New Application Page Limits: January 2010 Submissions

    http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-149.html

    Beginning with applications intended for the January 25, 2009, receipt date, all new (i.e., never submitted) and competing renewal applications will be required to use the newly-restructured application packages and adhere to shorter page limits for most mechanisms.

    Grant applications that were previously allowed 25 pages for the research strategy (R01, Ks) will now be allowed 12 pages; grant mechanisms previously allowed fewer than 25 pages (R21, R03) will now be reduced to 6 pages.

    Additionally, the application forms will be updated to reflect the response to NIH’s Enhancing Peer Review initiative. The application’s structure and format will now be aligned more closely with the review criteria. Please consult the most recent parent funding opportunity announcements to ensure download of the correct application forms.


    Clinical and Translational Research

    Clinical Trials and Epidemiological Studies

    NIDDK supports a wide range of clinical trials and epidemiological studies on chronic kidney disease.  While many of these programs are solicited by NIDDK through initiatives, investigators may also develop their own ideas.

    Areas of General Interest

    • Clinical trials to prevent or slow chronic renal disease
    • Epidemiology, prevention, and treatment of acute kidney injury
    • Epidemiologic and genetic studies of ESRD patients
    • Clinical trials to reduce mortality and morbidity in ESRD patients
    • Epidemiology of chronic renal insufficiency, including CV disease

    Mechanisms of Support

    NIDDK will support investigator-initiated, multi-center studies exclusively through a two-step application process, with an implementation planning grant (U34) application followed by a clinical study cooperative agreement (U01) application.


    If you have patients with Vesicoureteral Reflux (VUR)

     RIVUR (Randomized Intervention for Vesicoureteral Reflux)

    Multi-center trial of Trimethoprim-Sulfamethoxazole  prophylaxis compared to placebo in children with VUR.

    Study population:

    • Individuals between 2 months and 6 years of age with VUR and
    • Diagnosed urinary tract infection (UTI) with either fever or associated symptoms
    • Diagnosed with first UTI within 112 days prior to beginning study medication
    • Treated for the first UTI for 7 or more days with an effective drug

    For more information:

      See www.ClinicalTrials.gov identifier NCT00405704
      See http://www.cscc.unc.edu/rivur/


    Ongoing Studies/Currently Recruiting

     

    • Assessing Long Term Outcomes of Living Donation (ALTOLD)
      Multi-center prospective cohort study will address whether kidney donation increases the risk of developing ESRD and/or increases the risk of developing CV disease.

    • Participating sites: University of Minnesota (Hennepin County), Ohio State University, Mayo Clinic, University of Iowa, Johns Hopkins University, UCSF, University of Maryland.

     

    • Oral vs. IV Iron Therapy in Chronic Kidney Disease
      Single center study (Indiana University) investigating whether IV iron therapy in CKD is associated with more rapid decline in GFR than chronic oral iron therapy.
    • Randomized Intervention for Vesicoureteral Reflux (RIVUR)
      Multi-center trial of Trimethoprim-Sulfamethoxazole  prophylaxis compared to placebo in children with VUR (13 primary sites and 1 DCC).  Age range 2 months – 6 years.  Outcome measures will include frequency of UTI, changes in scarring measured by DMSA scan and development of antimicrobial resistance.
      (www.ClinicalTrials.gov identifier NCT00405704)


    Ongoing Studies/NOT Currently Recruiting

    • Clinical Trial of FSGS in Children and Young Adults
            Cooperative agreement-supported clinical trial; 3 primary centers and 1 DCC
    • Consortium for Radiologic Imaging Studies in PKD II (CRISP II)
            Cooperative agreement-supported clinical study; 4 centers and 1 DCC
    • Angiotensin II Blockade in Chronic Allograft Nephropathy (ABCAN)
            Cooperative agreement-supported clinical trial; single center at University of Minnesota
    • Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT)
            Cooperative agreement clinical trial; 20 centers and 1 DCC
    • Family Investigation of Nephropathy and Diabetes (FIND)
            Cooperative agreement-supported clinical study; 8 centers and 1 DCC
    • Chronic Renal Insufficiency Cohort (CRIC) Study
            Cooperative agreement-supported prospective epidemiological study: 7 centers and 1 DCC
    • Prospective Study of Chronic Kidney Disease in Children (CKiD)
            Cooperative agreement-supported clinical study; 2 centers and 1 DCC
    • Frequent Hemodialysis Network (FHN)
        Cooperative agreement-supported clinical study: 2 sites and 1
    • HALT-PKD
        Cooperative agreement-supported clinical study; 6 sites and 1 DCC
    • The NOCTURNAL TRIAL
        1 primary site and 1 DCC

    RIVUR Participating Sites:
    Oregon Health and Science University, University of Oklahoma Health Sciences Center, Texas Children’s Hospital, Children’s Mercy Hospital, University of Wisconsin Children’s Hospital, Children’s Memorial Hospital, Cincinnati Children’s Hospital, University of Alabama, Children’s Hospital of Michigan, Akron Children’s Hospital, Children’s Hospital of Pittsburgh, Wake Forest University Baptist Medical Center, Women and Children’s Hospital of Buffalo, Children’s National Medical Center, Johns Hopkins School of Medicine, Penn State Hershey Medical Center, Children’s Hospital of Philadelphia, Alfred I. DuPont Hospital for Children, Children’s Hospital of Boston


    Repository

    Central NIDDK Repositories
    Data, Biosamples, and DNA for your research

    http://www.NIDDKrepository.org


    The NIDDK Central Repositories store samples and data from NIDDK-funded clinical studies, which are made available to the community at the end of the study or when an interim phase is completed.

    Visit the NIDDK Repository Booth #1809!

     

     

    This box diagram shows the steps involved in obtaining data, biosamples or DNA from the central NIDDK repositories. First, the user requests the data and/or samples. The contractor (RTI) determines the availability of the samples requested and lets the user know this. NIDDK reviews the request and, if the use is appropriate, instructs RTI to send the user the requested data and/or samples. For additional instructions, please contact Helen Ray at RTI (phone 919-316-3418 or email hmp@rti.org

     

    Data and/or samples are available from:

    • African American Study of Kidney Disease and Hypertension (AASK)
      AASK compared the effectiveness of various antihypertensive regimens to slow or prevent progressive renal dysfunction in 1,094 African-Americans with a clinical diagnosis of hypertensive renal disease. 
    • Genetics of Kidneys in Diabetes (GoKinD)
      GoKinD created a repository of DNA and clinical information from adults with long-term Type 1 diabetes, with or without kidney disease to facilitate research into Type 1 diabetes and the genetic basis of diabetic kidney disease.  The collection includes case and control singletons as well as case and control trios.  In addition to phenotypic data, GWAS data from a 500K Affymetrix chip are available for all participants.
    • National Analgesic Nephropathy Study (NANS)
      NANS assesses the relationship between analgesic use and ESRD to learn if a non-contrasted CT scan can detect analgesic nephropathy. This is a case control study with detailed questionnaire and CT scan to > 200 incident ESRD patients and questionnaire to > 200 matched non-ESRD controls.
    • The Family Investigation of Nephropathy and Diabetes (FIND)
      The FIND group recruited nearly 7,000 individuals from four ethnic groups to study the genetic determinants of susceptibility to diabetic nephropathy.  Both family-based linkage and case-control strategies were used.  Linkage data from 5,000 individuals are available now.  GWAS data and samples will be available in 2010.
    • Epidemiology of Diabetes Interventions and Complications (EDIC)
      EDIC is a follow-up to DCCT (Diabetes Control and Complications Trial).  The DCCT demonstrated the efficacy of glycemic control for slowing the onset and progression of eye, kidney, and nerve complications and long-term diminution of CV complications.  Since 1994, most DCCT participants have been enrolled in EDIC for regular observational follow-up.  DCCT and EDIC family studies have collected data, DNA, and other biosamples from over 4,000 probands and relatives.  In addition to phenotypic data, GWAS data from a 500K Illumina chip are available for all DCCT participants and a small number of parents.
    • Modification of Diet in Renal Disease (MDRD)
      The multi-center MDRD study investigated whether restriction of dietary protein and phosphorus, and/or reduction of blood pressure below 140/90 reduces the rate of progression of chronic renal disease.  Patients with renal disease were randomized to either normal diets, a low protein/low phosphorus diet, or a very low diet supplemented with keto amino acids.  They were also randomized to a regimen to reduce blood pressure.
    • Hemodialysis Study (HEMO)
      The HEMO study tested the effects of the dose of dialysis and the level of flux of the dialyzer membrane on mortality and morbidity among patients undergoing maintenance hemodialysis.  The study randomized 1,846 patients to a standard or high dose of dialysis and to a dialyzer with a low-flux or high-flux membrane for dialysis three times a week.  The primary and secondary outcome showed that patients undergoing hemodialysis three times a week had no apparent major benefit from either a higher dialysis dose than that recommended by current U.S. guidelines or from the use of a high-flux membrane.
    • Consortium for Radiological Imaging Studies of PKD (CRISP)
      CRISP compared radiological techniques for measuring increases in renal volume during the progression of autosomal dominant polycystic kidney disease (ADPKD), testing whether magnetic resonance can detect changes in renal volume, cyst volume, or changes in % cystic involvement over a short period of time (1 to 2 years). CRISP participants had ADPKD with relatively normal renal function and creatinine clearances.  Data and samples from the first five years of the CRISP study are available.
    • Several diabetes studies, including the Diabetes Prevention
      Program (DPP) and the Diabetes Prevention Trial (DPT-1)


      IMPORTANT NIH CHANGES!!!

      New Human Embryonic Stem Cell Guidelines

      http://stemcells.nih.gov/policy/2009guidelines.htm

      Beginning July 7, 2009, NIH funds may support research utilizing hESCs derived from donated human embryos no longer needed for reproductive purposes. Documented assurance of voluntary informed consent needs to be obtained from the donors and the hESC line needs to be included in the NIH Registry.  Applicants may submit lines to the NIH Registry at http://stemcells.nih.gov/index.asp. 

      * Documents in PDF format require the free Adobe Acrobat Reader Exit Disclaimer Iconapplication for viewing.

      Page last updated: February 24, 2011

      General inquiries may be addressed to:
      Office of Communications & Public Liaison
      NIDDK, NIH
      Bldg 31, Rm 9A06
      31 Center Drive, MSC 2560
      Bethesda, MD 20892-2560
      USA
      301.496.3583

      The National Institutes of Health   Department of Health and Human Services   USA.gov is the U.S. government's official web portal to all federal, state, and local government web resources and services.  This website is certified by Health On the Net Foundation. Click to verify.